Tecfidera pushes Biogen revenue 40% higher in 2014
This article was originally published in Scrip
Executive Summary
On its way to becoming Biogen Idec's top-selling product, the oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) helped push the company's total revenue 40% higher on a year-over-year basis to $9.7bn for 2014.